This article was downloaded by: [New York University] On: 09 September 2013, At: 02:52 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn20

Impdh As A Biological Probe For Rna Antiviral Drug Discovery: Synthesis, Enzymology, Molecular Docking, And Antiviral Activity Of New Ribonucleosides With Surrogate Bases

Vasu Nair $^{\rm a}$, Xiaohui Ma $^{\rm a}$, Qingning Shu $^{\rm a}$, Fan Zhang $^{\rm a}$, Vinod Uchil $^{\rm a}$ & Govardhan R. Cherukupalli $^{\rm a}$

^a Center for Drug Discovery and the Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, Georgia, USA

Published online: 10 Dec 2007.

To cite this article: Vasu Nair , Xiaohui Ma , Qingning Shu , Fan Zhang , Vinod Uchil & Govardhan R. Cherukupalli (2007) Impdh As A Biological Probe For Rna Antiviral Drug Discovery: Synthesis, Enzymology, Molecular Docking, And Antiviral Activity Of New Ribonucleosides With Surrogate Bases, Nucleosides, Nucleotides and Nucleic Acids, 26:6-7, 651-654, DOI: <u>10.1080/15257770701490506</u>

To link to this article: <u>http://dx.doi.org/10.1080/15257770701490506</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at <u>http://www.tandfonline.com/page/terms-and-conditions</u>



IMPDH AS A BIOLOGICAL PROBE FOR RNA ANTIVIRAL DRUG DISCOVERY: SYNTHESIS, ENZYMOLOGY, MOLECULAR DOCKING, AND ANTIVIRAL ACTIVITY OF NEW RIBONUCLEOSIDES WITH SURROGATE BASES

Vasu Nair, Xiaohui Ma, Qingning Shu, Fan Zhang, Vinod Uchil, and Govardhan R. Cherukupalli Center for Drug Discovery and the Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, Georgia, USA

□ Our interest in the discovery of molecules with antiviral activity against RNA viruses led us to the design of ribonucleosides with surrogate bases with the intent of using inhibition of inosine monophosphate dehydrogenase (IMPDH) as a probe for antiviral drug discovery. A general methodology for the preparation of these compounds is discussed. Kinetic parameters of the inhibition studies with IMPDH, which were carried out spectrophotometrically by monitoring the formation of NADH, are given. Antiviral information and correlation of activity with IMPDH inhibition are discussed.

Keywords IMPDH inhibitors; synthesis; antiviral

INTRODUCTION

The enzyme, inosine monophosphate dehydrogenase (IMPDH; EC 1.1.1.205), catalyses the oxidative conversion of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP) with the involvement of the coenzyme, nicotinamide adenine dinucleotide (NAD⁺).^[1,2] IMPDH is an important target for the discovery of antiviral, anticancer, and immuno-suppressive agents.^[3] Consistent with this is the observation that some inhibitors of IMPDH have been found to have anticancer, antiviral and immunosuppressive activity.^[4–7] IMPDH is a sulfhydryl enzyme in which the Cys-331 residue in the active site may act as a nucleophilic participant in interactions with inhibitors that carry Michael acceptors at appropriate positions on the nucleobase.^[7–9] Participation of the Cys-331 is also consistent with the mechanism of substrate action of IMPDH, which involves

This project was supported by Grant No. AI056540 from the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. We thank Drs. E. Kern, R. Sidwell, and J. Huggins for antiviral screening results.

Address correspondence to Vasu Nair, Department of Pharmaceutical and Biomedical Sciences, Room 320, R.C. Wilson PH, The University of Georgia, Athens, GA 30602-2352, USA. E-mail: vnair@rx.uga.edu



FIGURE 1 Target molecules of this investigation.

covalent interaction of the enzyme and coenzyme (NAD⁺) complex with the 2-position of IMP.^[1] In an ongoing drug discovery program on RNA antiviral compounds in our laboratory,^[7,8,10,11] we have utilized IMPDH as a probe for the initial identification of potential antiviral molecules (Figure 1).

RESULTS AND DISCUSSION

A general and efficient synthetic approach to compounds of Figure 1 is illustrated in Scheme 1. Guanosine (11) was converted to the 2-iodo



SCHEME 1 A concise synthetic approach to C-2 functionalized inosine analogues.

Inhibitors	$K_i(\mu{ m M})^{a}$	$k_{\text{inact}}(s^{-1})^{b}$	$k_{\rm on} ({\rm M}^{-1} {\rm s}^{-1})^c$
1	3.98	0.029	0.73×10^{4}
2	_	_	2.12×10^4
3	4.25	0.013	0.33×10^4
5	1.11	0.027	2.67×10^4
6	no inhibition	_	_
8	81.8 (reversible)	_	_
9	74.4	0.023	3.05×10^2
10	4.70	0.030	_

TABLE 1 Data on inhibition of IMPDH by C-2 functionalized IMP analogues

 ${}^{a}K_{i} = K_{i,app}/(1 + [IMP])/K_{m}).$

 $bck_{on} = k_{inact}/K_i.$

compound 13 by acetylation and deamination/halogenation reactions. The key step in the synthesis was the palladium-catalyzed cross-coupling of intermediate 13 with functionalized stannanes^[12] to give 14. Deprotection under standard conditions gave the target molecules 15. For compounds, 8 and 9, the methodology used has been described previously by us.^[10]

Data from inhibition studies with inosine monophosphate dehydrogenase (IMPDH) from *E. coli* are summarized in Table 1. Details of the procedure for the enzyme kinetics are discussed.^[8,11] It is clear from the data that most of the target compounds are strong irreversible inhibitors of IMPDH.



FIGURE 2 Docking results of inhibitor 1 in the active site of IMPDH. The phosphate group is locked into position by polar interactions with Ile330, Gly366, Ser388 and Tyr411. The ribose hydroxyls form hydrogen bonds with Ser68 and Asp364. The backbone N-H of Gly415 and Met414, and C=O of Gln441stabilizes the base moiety by forming hydrogen bonds. The S atom of active residue Cys331 is 4.0 Å away from the 2-vinyl group terminal carbon. Cofactor NAD⁺ stacks with the base moiety of inhibitor.

Antiviral data on the target nucleosides correlate well with inhibition of IMPDH by their monophosphates (see^[7] for general mechanistic explanation). For example, the parent nucleosides of compounds **1**, **2**, **3**, **5**, and **10** show moderate to good antiviral activity against a number of RNA viruses and also against a few DNA viruses. Antiviral studies are continuing and the completed results will be published elsewhere.

REFERENCES

- 1. Hedstrom, L. IMP dehydrogenase: Mechanism of action and inhibition. *Curr. Med. Chem.* 1999, 6, 545–560.
- Goldstein, B.M.; Colby, T.D. IMP dehydrogenase: Structural aspects of inhibitor binding. *Curr. Med. Chem.* 1999, 6, 519–536.
- 3. De Clerq, E. Strategics in the design of antiviral drugs. Nature Rev. Drug Discovery 2002, 11, 13–25.
- Franchetti, P.; Grifantini, M. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. *Curr. Med. Chem.* 1999, 6, 599–614.
- Wang, W.; Papov, V.V.; Minakawa, N.; Matsuda, A.; Biemann, K.; Hedstrom, L. Inactivation of inosine 5/-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-β-D-ribofuranosylimidazole-4carboxamide 5/-monophosphate. *Biochemistry* 1996, 35, 95–101.
- Nair, V.; Ussery. M.A. New hypoxanthine nucleosides with RNA antiviral activity. *Antiviral Res.* 1992, 19, 173–178.
- Nair, V. IMPDH inhibitors: discovery of antiviral agents against emerging diseases. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats; Torrence, P.F., Ed., Wiley-Interscience: Hoboken, NJ, 2005, 179–202.
- 8. Pal, S.; Bera, B.; Nair, V. Inhibition of inosine monophosphate dehydrogenase (IMPDH) by the antiviral compound, 2-vinylinosine. *Bioorg. Med. Chem.* **2002**, 10, 3615–3618.
- Colby, T.D.; Vanderveen, K.; Strickler, M.D.; Markham, G.D.; Goldstein, B.M. Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design. *Proc. Natl. Acad. Sci. USA* **1999**, 96, 3531–3536.
- Nair, V.; Bera, B.; Kern, E.R. Synthesis and antiviral activities of 2-functionalized purine ribonucleosides. Nucleosides, Nucleotides Nucleic Acids 2003, 22, 115–127.
- 11. Nair, V.; Kamboj, R.C. Inhibition of inosine monophosphate dehydrogenase (IMPDH) by 2-[2-(Z)-fluorovinyl] inosine 5'-monophosphate. *Bioorg. Med. Chem. Lett.* **2003**, 13, 645–647.
- Nair, V.; Turner, G.A.; Chamberlain, S.D. Novel approaches to functionalized nucleosides *via* palladium-catalyzed cross-coupling with organostannanes. *J. Am Chem. Soc.* **1987**, 109, 7223–7224.